Valneva Announces Best Quarterly Results since Vivalis/Intercell Merger, Meets Business Objectives & Reconfirms Full Year Outlook

The Company posts balanced EBITDA and significantly reduced net loss

  • Balanced EBITDA of EUR 0.0m in Q3 2014 (vs EUR -5.5m in Q3 2013). While the Group still expects negative EBITDA in the near future due to R&D investments, it confirms its objective to be EBITDA profitable in the mid-term.
  • Net loss decreased to EUR 2.6m in Q3 2014 (vs EUR 10.0m in Q3 2013) benefiting from the positive impact of merger synergies and a strong improvement in the profitability of IXIARO®.
  • Revenues and grants were down to EUR 12.8m in Q3 2014 (vs EUR 14.7m in Q3 2013) mainly due to IXIARO®/JESPECT®’s fluctuating supply patterns and a decrease in collaboration and licensing revenues.
  • Cash position of EUR 36.9m at quarter-end, only slightly below cash position at end of previous quarter (EUR 37.3m).


  • Valneva reconfirms its 2014 overall IFRS revenue expectations of EUR 40 – 45 million and anticipates continued growth of IXIARO®/JESPECT® in-market sales.
  • The Company also reaffirms its prior guidance of a significant improvement of its operational results (excluding any non-cash amortization and impairment charges) in 2014 compared to the pro-forma financial performance of the combined two businesses (Vivalis and Intercell) in 2013. This improvement will be mainly due to EUR 5 – 6 million merger synergies and a strong improvement in the profitability of IXIARO®.
  • Valneva will continue to financially support the Group‘s strategy of focused spending in research and development in order to create long-term value through innovation while at the same time striving towards mid-term financial break-even. Valneva confirms that its key research and development projects are progressing according to plan.

The condensed consolidated interim financial report is available on the Company’s website

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)